All Updates

All Updates

icon
Filter
Partnerships
BigHat Biosciences collaborates with Janssen Biotech for next-gen protein therapeutics design
AI Drug Discovery
Apr 24, 2024
This week:
Product updates
Pimax announces compact Dream Air VR headset for USD 1,900
Extended Reality
Dec 23, 2024
Funding
HuLoop raises Series A funding from Mighty Capital
Workflow Automation Platforms
Dec 23, 2024
M&A
Fiserv to acquire Payfare for undisclosed sum to enhance embedded finance solutions
Financial Wellness Tools
Dec 23, 2024
M&A
Fiserv to acquire Payfare for undisclosed sum to enhance embedded finance solutions
FinTech Infrastructure
Dec 23, 2024
Funding
Meight raises EUR 3.4 million in funding led by Cusp Capital
Smart Mobility Information
Dec 23, 2024
Regulation/policy
Desktop Metal sues Nano Dimension over merger compliance
Additive Manufacturing
Dec 23, 2024
Management news
Nexa3D scales back operations amid financial crisis
Additive Manufacturing
Dec 23, 2024
Funding
Fraction AI raises USD 6 million in pre-seed funding to scale hybrid data labeling
Machine Learning Infrastructure
Dec 23, 2024
Last week:
Partnerships
Rocket Lab launches sixth Synspective radar satellite as part of ongoing partnership
Space Travel and Exploration Tech
Dec 21, 2024
Partnerships
EHang partners with Changan Automobile to develop eVTOL aircraft for personal transportation
Passenger eVTOL Aircraft
Dec 21, 2024
AI Drug Discovery

AI Drug Discovery

Apr 24, 2024

BigHat Biosciences collaborates with Janssen Biotech for next-gen protein therapeutics design

Partnerships

  • BigHat Biosciences has teamed up with Janssen Biotech in a strategic collaboration to develop novel therapeutics using the companies' combined expertise in drug discovery and AI/ML. The terms and financial details of the partnership have not been disclosed.

  • This collaboration targets the discovery and verification of potential proteins, as well as simplifying the design of antibodies and other treatments for a range of conditions, from chronic illnesses to life-threatening diseases. It hopes to achieve this by using BigHat's proprietary AI/ML-powered platform, Milliner, and Janssen’s drug development and data science expertise.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.